1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
Delayed Swiss Exchange  -  05/20 11:30:40 am EDT
55.20 CHF   +0.36%
04/22BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/22BB Biotech Swings To Q1 Loss As Total Returns Plummet
MT
04/22BB Biotech AG publishes its interim report
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BB Biotech : Interim report as at March 31, 2021

04/25/2021 | 09:12am EDT

BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential.

Disclaimer

BB Biotech AG published this content on 23 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2021 13:11:09 UTC.


© Publicnow 2021
All news about BB BIOTECH AG
04/22BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/22BB Biotech Swings To Q1 Loss As Total Returns Plummet
MT
04/22BB Biotech AG publishes its interim report
EQ
04/22BB BIOTECH AG : Increased investment level balanced by established core holdings
EQ
04/12GLOBAL MARKETS LIVE : Honda, Shopify, Meta, ASOS, Gilead Sciences...
04/12BB Biotech Launches New Share Repurchase Program
MT
04/12BB Biotech AG concludes its share buyback program and launches a new buyback program
EQ
04/12Tranche Update on BB Biotech AG’s Equity Buyback Plan announced on April 11, 2019.
CI
04/12BB Biotech AG authorizes a Buyback Plan.
CI
04/12BB Biotech AG announces an Equity Buyback.
CI
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Financials
Sales 2022 796 M 815 M 815 M
Net income 2022 497 M 509 M 509 M
Net Debt 2022 278 M 285 M 285 M
P/E ratio 2022 4,16x
Yield 2022 7,32%
Capitalization 3 043 M 3 119 M 3 119 M
EV / Sales 2022 4,18x
EV / Sales 2023 4,98x
Nbr of Employees 10
Free-Float 98,1%
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 55,20 CHF
Average target price 75,13 CHF
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG-28.45%3 119
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567